Table 3. DDI-Myopathy Analysis Adjusted for Age and Sex.

population	drugs	Na	Ma	riskb	relative risk/P-valuec
all	statinsd alone	88,682	8,149	9.2%	1.87/0.05
	CQ and statinsd	58	10	17.2%
women	statinsd alone	44,212	4,234	9.6%	2.28/0.03*
	CQ and statinsd	32	7	21.9%
men	statinsd alone	44,123	3,743	8.5%	1.35/0.48
	CQ and statinsd	26	3	11.5%
>50 yearse	statinsd alone	50,322	5,347	10.6%	1.89/0.06
	CQ and statinsd	40	8	20.0%
<50 yearse	statinsd alone	33,413	2,732	8.2%	1.35/0.65
	CQ and statinsd	18	2	11.1%

^aN: Number of patients taking drug. M: Number of myopathies. N and M represent sums of counts for each individual statin.

^bRisk is calculated as M/N × 100%.

^cRelative risk is calculated as risk (CQ and statins)/risk (statins alone).

Statistical analysis was performed with the Chi-square test.

^*indicates a statistically significant difference (p < 0.05) (CQ and statins vs statins alone).

^dStatins: rosuvastatin, pravastatin, and pitavastatin.

^eAge.